Trial record 1 of 1 for:    4130-CL-0201
Previous Study | Return to List | Next Study

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01478594
First received: November 21, 2011
Last updated: June 9, 2015
Last verified: June 2015
  Purpose

The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in combination with mFOLFOX6.


Condition Intervention Phase
Colorectal Cancer
Drug: Tivozanib
Drug: Bevacizumab
Drug: mFOLFOX6
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects

Resource links provided by NLM:


Further study details as provided by AVEO Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Investigator-assessed Progression-Free Survival (PFS) [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]

    The time from the date of randomization until objective tumor progression or death due to any cause. Objective tumor progression was determined through radiological imaging and based on the requirements of the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1):

    Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.

    Participants who did not progress or had not died at the time of the analysis were censored at the date of last tumor assessment where non-progression was documented.



Secondary Outcome Measures:
  • Progression-Free Survival (PFS) Based on Independent Radiological Review (IRR) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    The time from the date of randomization until the date of radiological disease progression assessed by the IRR or until death due to any cause, even in the absence of radiological progression.

  • Overall Survival (OS) [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    Overall survival (OS) is defined as the time from the date of randomization until the documented date of death. Participants still alive at the time of analysis were censored on the last day the participant was known to be alive.

  • Objective Response Rate (ORR) [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]

    Objective response rate is defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) confirmed a minimum of four weeks apart based on RECIST 1.1 criteria.

    CR: Disappearance of all target and non-target lesions and no new lesions.

    PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and no progression of non-target lesions and no new lesions, or, disappearance of all target lesions and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.


  • Duration of Response (DoR) [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    Duration of response (DoR) is defined as the time from the date of the first documented response of CR or PR (whichever is first recorded) to documented progression or death. If a participant did not progress or had not died at the time of analysis, the duration of response was censored at the date of last tumor assessment. Duration of response is only defined for participants whose best overall response was CR or PR.

  • Time to Treatment Failure (TTF) [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    Time to Treatment Failure (TTF) is defined as the time from randomization to last dose date of tivozanib/bevacizumab. If a participant discontinued treatment for any reason, the participant was considered as an event. Participants remaining on treatment at the time of analysis were censored at date of last dose.

  • Health Related Quality of Life (HRQoL) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Time to deterioration in HRQoL measured by Colorectal cancer (CRC) subscale of the Functional Assessment of cancer Therapy Colorectal (FACT-C) scale, change in score from baseline using the European Quality of Life - 5 Dimensions (EQ-5D) and Fact Colorectal Symptom Index (FCSI) were not evaluated due to study closure.

  • Safety as Assessed by Physical Examination, Vital Signs, Laboratory Assessments, 12-lead Electrocardiogram (ECGs), and Adverse Events (AEs) [ Time Frame: From first dose through 30 days after last dose of either tivozanib or bevacizumab, until the data cut-off date of 28 February 2014. The median duration of treatment was 168.0 days in the tivozanib (tiv) arm and 162.0 days in the bevacizumab (bev) arm. ] [ Designated as safety issue: No ]

    An abnormality identified during a medical test is defined as an AE if the abnormality induced clinical signs or symptoms, required active intervention, interruption or discontinuation of study medication or was clinically significant in the investigator's opinion.

    An AE was serious if it resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required or prolonged inpatient hospitalization or other medically important event.

    AEs, including abnormal clinical laboratory values, were graded using the National Cancer Institute Common Terminology Criteria for Grading Adverse Events (NCI-CTCAE) Version 4.03 per the following: 1=mild; 2= moderate; 3= severe; 4= life threatening; 5=death.

    Treatment-related AEs were defined as events where the relationship to study drug was marked as probably or possibly, or was missing.


  • Progression-free Survival Events by Lactate Dehydrogenase (LDH) Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum lactate dehydrogenase status.

  • Progression-free Survival Events by Serum Vascular Endothelial Growth Factor-A (VEGF-A) Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum vascular endothelial growth factor-A (VEGF-A) level. VEGF-A protein levels were quantified using enzyme-liked immunosorbent assay (ELISA); the level of protein is expressed relative to the observed median level.

  • Progression-free Survival Events by Serum Vascular Endothelial Growth Factor-C (VEGF-C) Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum VEGF-C level. VEGF-C protein levels were quantified using enzyme-liked immunosorbent assay (ELISA); the level of protein is expressed relative to the observed median level.

  • Progression-free Survival Events by Serum VEGF-C / VEGF-A Ratio [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum VEGF-C/VEGF-A ratio. VEGF-A and VEGF-C protein levels were quantified using enzyme-liked immunosorbent assay (ELISA); the ratio is expressed relative to the observed median.

  • Progression-Free Survival Events by Soluble Vascular Endothelial Growth Factor Receptor-2 (sVEGFR-2) Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum sVEGFR-2 level. sVEGFR-2 protein levels were quantified using enzyme-liked immunosorbent assay (ELISA); the level of protein is expressed relative to the observed median level.

  • Progression-Free Survival Events by Soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3) Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum sVEGFR-3 level. sVEGFR-3 protein levels were quantified using enzyme-liked immunosorbent assay (ELISA); the level of protein is expressed relative to the observed median level.

  • Progression-Free Survival Events by Serum Interleukin-8 (IL-8) Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum interleukin-8 level. IL-8 protein levels were quantified using enzyme-liked immunosorbent assay (ELISA); the level of protein is expressed relative to the observed median level.

  • Progression-Free Survival Events by Serum Neuropilin Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]
    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline serum neuropilin level. Neuropilin protein levels were quantified using enzyme-liked immunosorbent assay (ELISA); the level of protein is expressed relative to the observed median level.

  • Progression-Free Survival Events by Tumor VEGF-A Ribonucleic Acid (RNA) Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]

    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline tumor VEGF-A RNA level.

    RNA was purified from biopsy tissue and measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Since low cycle threshold (CT) values reflect high RNA expression, the inverse of CT values were used to derive tumor categories. RNA level is expressed relative to the observed median level.


  • Progression-Free Survival Events by Tumor VEGF-C RNA Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]

    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline tumor VEGF-C RNA level.

    RNA was purified from biopsy tissue and measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Since low cycle threshold (CT) values reflect high RNA expression, the inverse of CT values were used to derive tumor categories. RNA level is expressed relative to the observed median level.


  • Progression-Free Survival Events by Tumor VEGF-C / VEGF-A RNA Ratio [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]

    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline tumor VEGF-C/VEGF-A RNA ratio.

    RNA was purified from biopsy tissue and measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Since low cycle threshold (CT) values reflect high RNA expression, the inverse of CT values were used to derive tumor categories. RNA level is expressed relative to the observed median level.


  • Progression-Free Survival Events by Tumor VEGF-D RNA Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]

    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline tumor VEGF-D RNA level.

    RNA was purified from biopsy tissue and measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Since low cycle threshold (CT) values reflect high RNA expression, the inverse of CT values were used to derive tumor categories. RNA level is expressed relative to the observed median level.


  • Progression-Free Survival Events by Tumor Placental Growth Factor (PIGF) RNA Level [ Time Frame: From randomization until the analysis cut-off date of 13 September 2013; median time on study drug was 167 days in the tivozanib group and 162 days in the bevacizumab group. ] [ Designated as safety issue: No ]

    The number of participants with a progression-free survival event (radiological progression assessed by the investigator or death due to any cause) reported by Baseline tumor PIGF RNA level.

    RNA was purified from biopsy tissue and measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Since low cycle threshold (CT) values reflect high RNA expression, the inverse of CT values were used to derive tumor categories. RNA level is expressed relative to the observed median level.



Enrollment: 265
Study Start Date: December 2011
Study Completion Date: January 2015
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tivozanib + mFOLFOX6
Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
Drug: Tivozanib
Capsules for oral administration
Other Names:
  • AV951
  • ASP4130
Drug: mFOLFOX6
mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
Active Comparator: Bevacizumab + mFOLFOX6
Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
Drug: Bevacizumab
Solution for intravenous infusion
Other Name: Avastin
Drug: mFOLFOX6
mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.

Detailed Description:

Imaging scans (computed tomography [CT]/magnetic resonance imaging [MRI]) to assess disease progression were to be completed within 28 days prior to first study drug administration, approximately every 8 weeks for the first 18 months and then approximately every 12 weeks until the patient showed progressive disease (PD) per the investigator, withdrew consent, was lost to follow-up or died. Per the original protocol, all patients were to be contacted by the study site every 12 weeks for survival following the end-of-treatment visit until death or for no more than 3 years after the end-of-treatment visit.

The interim futility analysis was conducted in December 2013, based on a pre-specified analysis cutoff date of 13 September 2013. The study was brought to a close as specified in the protocol due to the results of the interim futility analysis and only those participants who were deriving benefit (per the treating physician) from their current treatment remained on study until one of the discontinuation criteria was met.

Given the early closure of the study, no updated or additional efficacy analyses were performed after the interim analysis. A biomarker analysis was conducted in January 2014, based on the data from the cutoff date of 13 September 2013. The safety analysis was updated with a new cutoff date of 28 February 2014.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented diagnosis of metastatic colorectal cancer
  • One measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • No prior systemic chemotherapy for advanced colorectal cancer; no fluorouracil containing adjuvant therapy in previous 6 months
  • Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

Exclusion Criteria:

  • Any prior Vascular Endothelial Growth Factor (VEGF)-directed therapy or any other agent or investigational agent targeting the VEGF pathway
  • Primary Central Nervous System (CNS) malignancies or CNS metastases
  • Hematologic abnormalities:

    • Hemoglobin < 9.0 g/dL,
    • Absolute neutrophil count (ANC) < 2000 per mm^3,
    • Platelet count < 100,000 per mm^3,
    • Prothrombin (PT) or Partial Thromboplastin Time (PTT) > 1.5 X Upper Limit of Normal (ULN)
  • Serum chemistry abnormalities:

    • Total bilirubin > 1.5 X ULN,
    • Aspartate aminotransferase (AST) or Alanine Aminotransferase (ALT) > 2.5 X ULN,
    • Alkaline phosphatase > 2.5 X ULN,
    • Serum albumin < 2.0 g/dL,
    • Creatinine > 1.5 X ULN,
    • Proteinuria > 2+ by urine dipstick
  • Significant cardiovascular disease
  • Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug
  • Non-healing wound, bone fracture, or skin ulcer
  • Inadequate recovery from any prior surgical procedure or major surgical procedure within 8 weeks prior to administration, or anticipation of major surgical procedure during the course of the study
  • History of significant gastrointestinal (GI) toxicity, diarrhea, or stomatitis within the last 6 weeks
  • An active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug
  • Serious/active infection or infection requiring antibiotics
  • Significant bleeding disorders within 6 months prior to administration of first dose of study drug
  • Active second primary malignancy, other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular carcinoma in situ of the breast. Subject is not considered to have a currently active malignancy if they have completed anti-cancer therapy and have been disease free for > 5 years
  • History of allergic reactions, or intolerance, attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, history of Grade 3 hypersensitivity to oxaliplatin, history of allergic reaction to folic acid
  • Female subject is pregnant or lactating
  • Known history of genetic or acquired immune suppression disease including Human Immunodeficiency Virus (HIV); subjects on immune suppressive therapy for organ transplant
  • Inability to swallow pills, malabsorption syndrome or gastrointestinal disease, major resection of the stomach or small bowel, or gastric bypass
  • Uncontrolled neuro-psychiatric disorder or altered mental status
  • Peripheral neuropathy ≥ Grade 2
  • Participating in another interventional protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01478594

  Hide Study Locations
Locations
United States, Arizona
Banner MD Anderson Cancer Research Center
Gilbert, Arizona, United States, 85234
Genesis Cancer Center
Hot Springs, Arizona, United States, 71913
Arizona Clinical Research Center
Tucson, Arizona, United States, 85715
United States, California
University of California San Diego-Morris Cancer Center
La Jolla, California, United States, 92093
UC Irvine Medical Center, Division of Hematology/Oncology
Orange, California, United States, 92868
Desert Hematology Oncology Medical Group, Inc.
Rancho Mirage, California, United States, 92270
United States, Colorado
Mountain Blue Cancer Care Center
Golden, Colorado, United States, 80033
United States, Florida
University of Florida, Davis Cancer Center (VA)
Gainesville, Florida, United States, 32610
Cleveland Clinic Florida
Weston, Florida, United States, 33331
United States, Hawaii
University of Hawaii
Honolulu, Hawaii, United States, 96813
Queen's Medical Center
Honolulu, Hawaii, United States, 96813
Kaiser Foundation Hospitals
Honolulu, Hawaii, United States, 96819
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Illinios Cancer Care
Peoria, Illinois, United States, 61615
United States, Indiana
Investigative Clinical Research of Indiana, LLC
Indianapolis, Indiana, United States, 46260
Horizon Oncology Research, Inc.
Lafayette, Indiana, United States, 47905
United States, Maryland
Associates of Oncology Hematology, P.C.
Rockville, Maryland, United States, 20850
United States, Michigan
University of Michigan Health
Ann Arbor, Michigan, United States, 48109
United States, New York
NYU Cancer Institute
New York, New York, United States, 10016
United States, North Carolina
Alamance Regional Medical Center
Burlington, North Carolina, United States, 27215
United States, Ohio
Tri Country Hematology / Oncology
Canton, Ohio, United States, 44718
Signal Point Clinical Research Center, LLC
Middletown, Ohio, United States, 45042
United States, Oklahoma
Cancer Care Associates
Tulsa, Oklahoma, United States, 74136
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Oncology Hematology of Lehigh Valley
Bethlehem, Pennsylvania, United States, 18015
United States, Utah
Northern Utah Associates
Ogden, Utah, United States, 84403
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Australia, New South Wales
St George Hospital
Kogarah, New South Wales, Australia, 2217
Tweed Hospital
Tweed Heads, New South Wales, Australia, 2485
Calvary Mater Newcastle
Waratah, New South Wales, Australia, 2298
Australia, South Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia, 5042
Australia, Tasmania
Royal Hobart Hospital
Hobart, Tasmania, Australia, 7000
Australia, Victoria
Ballarat Health Services
Ballarat, Victoria, Australia, 3350
Cabrini Hospital Malvern
Malvern, Victoria, Australia, 3144
Border Medical Oncology
Wodonga, Victoria, Australia, 3690
Austria
Medizinische Universitat Graz
Graz, Austria, 8036
Salzburger Landesklinken
Salzburg, Austria, 5020
Klinikum Wels-Grieskirchen GmbH
Wels, Austria, 4600
Belgium
Ziekenhuisnetwerk Antwerpen - AZ Middelheim
Antwerpen, Belgium, 2020
Imelda VZW
Bonheiden, Belgium, 2820
AZ Sint-Lucas Brugge
Brugge, Belgium, 8310
AZ Groeninge - Campus Sint-Niklaas
Kortrijk, Belgium, 8500
Canada, British Columbia
British Columbia Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Nova Scotia
QEII Health Science Centre
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Quebec
Hopital De La Cite-De-La-Sante
Laval, Quebec, Canada, H7M 3L9
Hopital Saint-Luc - Pavillon Principal
Montreal, Quebec, Canada, H2X 3J4
Canada
Chuq Centre Hospitalier Universitaire De Quebec
Quebec, Canada, G1R 2J6
Czech Republic
Masarykuv onkologicky ustav
Brno, Czech Republic, 656 53
Fakultni nemocnice Hradec Kralove
Hradec Kralove, Czech Republic, 500 05
Finland
Tampereen yliopistollinen sairaala
Tampere, Finland, FI-33520
Turun yliopistollinen keskussairaala
Turku, Finland, FI-20520
Hungary
Orszagos Onkologiai Intezet
Budapest, Hungary, 1122
Petz Aladar Megyei Oktato Korhaz
Gyor, Hungary, 9024
Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza
Gyula, Hungary, 5700
Fejer Megyei Szent Gyorgy Korhaz
Szekesfehervar, Hungary, 8000
Italy
Azienda Ospedaliero- Universitaria di Bologna - Policlinico S.Orsola-Malpighi
Bologna, Italy, 40128
Fondazione del Piemonte per I'Oncologia IRCC
Candiolo, Italy, 10060
IRCCS Azienda Ospedaliera Universitaria San Martino - Istituto Nazionale per la Ricerca sul Cancro
Genova, Italy, 16132
Istituto Clinico Humanitas
Rozzano (MI), Italy, 20089
Netherlands
Amphia Ziekenhuis
Breda, Netherlands, 4819 EV
Spain
Hospital Universitario Miguel Servet
Zaragoza, Aragon, Spain, 50009
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain, 39008
Corporacio Sanitaria Parc Tauli
Sabadell, Cataluna, Spain, 08208
Hospital Mutua de Terrassa
Terrassa, Cataluna, Spain, 08221
Centro Oncologico de Galicia
Galicia, Spain, 15009
Centro Integral Oncologico Clara Campal
Madrid, Spain, 28050
United Kingdom
Addenbrooke's Hospital
Cambridge, United Kingdom, CB2 2QQ
Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
Beatson West of Scotland Cancer Center
Glasgow, United Kingdom, G12 0YN
University College Hospital
London, United Kingdom, NW1 2BU
Maidstone Hospital
Maidstone, United Kingdom, ME16 9QQ
Christie Hospital
Manchester, United Kingdom, M20 4BX
Peterborough and Stamford Hospitals NHS Foundation Trust
Peterborough, United Kingdom, PE3 6DA
Sponsors and Collaborators
AVEO Pharmaceuticals, Inc.
Investigators
Study Director: Medical Director AVEO Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: AVEO Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01478594     History of Changes
Other Study ID Numbers: 4130-CL-0201, 2011-003502-24
Study First Received: November 21, 2011
Results First Received: February 19, 2015
Last Updated: June 9, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Belgium: Federal Agency for Medicinal Products and Health Products
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Czech Republic: State Institute for Drug Control
Australia: Department of Health and Ageing Therapeutic Goods Administration
Italy: The Italian Medicines Agency
Spain: Ministry of Health and Consumption
Austria: Agency for Health and Food Safety
Finland: Finnish Medicines Agency
Hungary: National Institute of Pharmacy
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by AVEO Pharmaceuticals, Inc.:
metastatic colorectal cancer
Avastin
bevacizumab
tivozanib
mFOLFOX6
BATON-CRC
AV951
ASP4130

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on July 30, 2015